A Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia in Pediatric Participants With Chronic Kidney Disease
Stopped Several factors contributed to significant challenges in enrollment and led the Sponsor to discontinue the AMAG-FER-CKD-251 study as designed.
Conditions
Interventions
- DRUG: Ferumoxytol
- DRUG: Oral Iron
Sponsor
AMAG Pharmaceuticals, Inc.